A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Biomarker
- Acronyms PD Nilotinib
- 06 Feb 2017 Planned End Date changed from 1 Apr 2018 to 1 Jul 2020.
- 06 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2020.
- 06 Feb 2017 Status changed from not yet recruiting to recruiting.